Brincidofovir

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Double-stranded DNA Virus

Conditions

Double-stranded DNA Virus

Trial Timeline

Dec 1, 2010 → Dec 1, 2012

NCT ID

NCT01143181

About Brincidofovir

Brincidofovir is a phase 3 stage product being developed by Jazz Pharmaceuticals for Double-stranded DNA Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01143181. Target conditions include Double-stranded DNA Virus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02596997	Pre-clinical	Completed	—	—	Adenovirus
NCT03339401	Phase 2	Terminated	Dec 22, 2017	May 10, 2019	Adenovirus
NCT02420080	Pre-clinical	Terminated	Feb 1, 2015	Sep 1, 2016	Adenovirus
NCT04268966	Phase 2	Withdrawn	Oct 1, 2014	Dec 1, 2015	Ebola Virus Disease
NCT02087306	Phase 3	Completed	Mar 1, 2014	Aug 1, 2016	Adenovirus Infection
NCT01769170	Phase 3	Completed	Aug 1, 2013	Jan 1, 2016	CMV
NCT01143181	Phase 3	Completed	Dec 1, 2010	Dec 1, 2012	Double-stranded DNA Virus
NCT01241344	Phase 2	Completed	Nov 1, 2010	Jun 1, 2013	Adenovirus Disease

Other Products from Jazz Pharmaceuticals

Sativex + PlaceboApproved

Sodium OxybateApproved

JZP258Approved

Solriamfetol + PlaceboApproved

Placebo + Sodium OxybateApproved